Effect of Vitamin D-supplementation on Bone Markers (serum P1NP and CTX): A Randomized, Double Blinded, Placebo Controlled Trial Among Healthy Immigrants Living in Norway
Overview
Authors
Affiliations
Objective: Vitamin D is essential for the maintenance of calcium homeostasis and bone mineralization; and low serum 25-hydroxyvitamin D (s-25-(OH)D) concentrations are associated with increased bone turnover. However, there is a lack of randomized controlled trials that have investigated the effect of vitamin D treatment on bone turnover in immigrant populations. We aimed to investigate the effect of 16-week daily vitamin D supplementation on bone formation marker serum procollagen type 1 amino-terminal propeptide (P1NP) and bone resorption marker C-terminal crosslinked telopeptide of type I collagen (CTX).
Design: Double-blind, randomized, placebo-controlled trial.
Setting: Immigrant community centers in Oslo, Norway.
Participants: 251 healthy adults aged 18-50 years with a non-Western immigrant background were recruited.
Intervention: 16 weeks of daily oral supplementation with either 10 μg vitamin D, 25 μg vitamin D, or placebo.
Main Outcome Measures: Difference in change during the 16-week intervention between the intervention groups combined (10 or 25 μg of vitamin D/day) and placebo, in serum P1NP and serum CTX.
Results: A total of 214 (85%) participants completed the study. S-25-(OH)D increased from 29 nmol/L at baseline to 49 nmol/L in the intervention group with no significant change in the placebo group. However, there was no difference in change of serum P1NP (mean difference: - 1.2 μg/L (95% CI: - 5.4, 2.9, P = 0.6)) and serum CTX (mean difference: - 0.005 μg/L (95% CI: - 0.03, 0.02, P = 0.7)) between those receiving vitamin D supplementation compared with placebo. The plasma PTH had decreased by a mean of - 1.97 pmol/L (95% CI: - 2.7, - 1.3, P < 0.0001) in the vitamin D group compared to placebo.
Conclusions: Supplementation with 10 or 25 μg oral vitamin D during winter and spring for 16 weeks did not significantly affect serum P1NP and serum CTX, despite increasing s-25(OH)D and decreasing PTH in a healthy immigrant population with low baseline vitamin D status. Trial registration number: NCT01263288.
Persia S, Holmlund-Suila E, Valkama S, Enlund-Cerullo M, Rosendahl J, Andersson S Endocr Connect. 2024; 14(1.
PMID: 39555588 PMC: 11728877. DOI: 10.1530/EC-24-0482.
Thomas L, Dissanayake L, Tahmasbi M, Staruschenko A, Al-Masri S, Dominguez Rieg J Sci Rep. 2024; 14(1):16997.
PMID: 39043847 PMC: 11266651. DOI: 10.1038/s41598-024-67839-4.
Jeong C, Ha J, Yoo J, Lee Y, Kim J, Ha Y J Bone Metab. 2023; 30(2):189-199.
PMID: 37449351 PMC: 10345998. DOI: 10.11005/jbm.2023.30.2.189.
Stewart C, OHara N, Bzovsky S, Bahney C, Sprague S, Slobogean G Bone Joint Res. 2022; 11(4):239-250.
PMID: 35442058 PMC: 9057525. DOI: 10.1302/2046-3758.114.BJR-2021-0226.R1.
Migration health research in Norway: a scoping review.
Laue J, Diaz E, Eriksen L, Risor T Scand J Public Health. 2021; 51(3):381-390.
PMID: 34609260 PMC: 10251465. DOI: 10.1177/14034948211032494.